Tudor Investment Corp ET AL Buys 17,233 Shares of CorVel Corp. $CRVL

Tudor Investment Corp ET AL raised its stake in CorVel Corp. (NASDAQ:CRVL) by 17.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 114,116 shares of the business services provider’s stock after acquiring an additional 17,233 shares during the quarter. Tudor Investment Corp ET AL owned about 0.22% of CorVel worth $8,835,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in CRVL. Norges Bank bought a new position in shares of CorVel during the second quarter worth approximately $34,418,000. Thrivent Financial for Lutherans increased its holdings in shares of CorVel by 187.9% during the second quarter. Thrivent Financial for Lutherans now owns 400,003 shares of the business services provider’s stock worth $41,112,000 after purchasing an additional 261,049 shares during the period. Qube Research & Technologies Ltd increased its holdings in shares of CorVel by 100.9% during the third quarter. Qube Research & Technologies Ltd now owns 236,713 shares of the business services provider’s stock worth $18,326,000 after purchasing an additional 118,879 shares during the period. Algert Global LLC increased its holdings in shares of CorVel by 73.4% during the third quarter. Algert Global LLC now owns 217,559 shares of the business services provider’s stock worth $16,843,000 after purchasing an additional 92,077 shares during the period. Finally, Cubist Systematic Strategies LLC increased its holdings in shares of CorVel by 249.0% during the second quarter. Cubist Systematic Strategies LLC now owns 117,395 shares of the business services provider’s stock worth $12,066,000 after purchasing an additional 83,757 shares during the period. 51.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of CorVel in a report on Friday, January 9th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Insider Buying and Selling at CorVel

In other CorVel news, insider Maxim Shishin sold 2,400 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $54.00, for a total transaction of $129,600.00. Following the sale, the insider owned 7,050 shares of the company’s stock, valued at approximately $380,700. The trade was a 25.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 44.56% of the company’s stock.

CorVel Price Performance

Shares of NASDAQ:CRVL opened at $54.06 on Tuesday. The company’s 50 day simple moving average is $53.33 and its 200 day simple moving average is $65.65. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of 26.50 and a beta of 1.05. CorVel Corp. has a 1 year low of $44.83 and a 1 year high of $119.57.

CorVel (NASDAQ:CRVL) last announced its quarterly earnings data on Tuesday, February 3rd. The business services provider reported $0.47 earnings per share (EPS) for the quarter. The business had revenue of $235.63 million for the quarter. CorVel had a net margin of 11.23% and a return on equity of 30.15%.

CorVel Profile

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).